emjreviews.com
Cure8 news brief
IBD Biomarker Supported by Red Cell Distribution Width Analysis - EMJ
Tests and monitoring
Biomarkers
Biomarker
Remission
Systematic Review or Meta Analysis
Adult patients
Clinicians
Researchers
Why This Matters
RDW is a cheap, routinely measured blood parameter; if it reliably reflects IBD presence or activity, it could be an easy additional tool to help detect flares or support assessment without extra testing.
Who Should Pay Attention
Adult patients with IBD, clinicians who manage IBD (gastroenterologists, IBD nurses), and researchers interested in biomarkers for disease monitoring.
Study Snapshot
Story typeResearch news
Evidence typeSystematic Review or Meta Analysis
Source depthFull source text
What To Know
A systematic review and meta-analysis published in BMC Gastroenterology and summarised by EMJ Reviews reports that red blood cell distribution width (RDW) — a routine component of complete blood counts — was consistently higher in people with Crohn’s disease and ulcerative colitis versus healthy controls, and higher during active disease versus remission.
The pooled analyses showed mean differences in RDW for Crohn’s disease and ulcerative colitis and identified an RDW threshold (>14%) with reasonable sensitivity and specificity for distinguishing active Crohn’s disease from remission in the analyzed studies.
These findings describe RDW as an inexpensive, widely available blood parameter that may help support clinical assessment of IBD alongside established measures.
The study used PRISMA methods and pooled data up to September 2025, but the EMJ summary does not provide details on heterogeneity between studies, possible confounders (for example, concurrent anemia, iron status, or inflammation from other causes), or whether RDW adds independent predictive value beyond existing biomarkers such as CRP or fecal calprotectin.
If considering RDW in practice, clinicians would need to interpret it alongside the full clinical picture and other tests; the article presents RDW as a supportive biomarker rather than a standalone diagnostic or monitoring tool.
Keep In Mind
The EMJ article summarises a systematic review and meta-analysis (BMC Gastroenterology 2026). The summary does not detail study-by-study differences, adjustment for anemia or iron deficiency, or direct comparisons against established markers; those details would affect how RDW could be applied in practice.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationemjreviews.com
AuthorsSean Boyle
Indexed viaGoogle News
Source typeWeb article
PublishedAug 9, 2026, 12:04 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
“The role of red cell distribution width in inflammatory bowel disease evaluation: a comprehensive systematic review and meta-analysis”
RDW is part of a routine complete blood count and, if reliably associated with IBD activity, could offer a low-cost, widely available adjunctive biomarker for detecting disease and monitoring activity.
"The role of red cell distribution width in inflammatory bowel disease evaluation: a comprehensive systematic review and meta-analysis".
The review suggests RDW, an inexpensive and widely available blood test parameter, is higher in IBD and correlates with disease activity—meaning it might help clinicians monitor disease alongside other tests.
Evaluation of serum human galectin 3 as a marker of activity in inflammatory bowel disease in comparison to fecal calprotectin.
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.